The TrialSite recently reported that Baylor University Medical Center recently announced its initiative to study leronlimab, an investigational drug for HIV infections that is under evaluation due to its apparent ability to inhibit lung inflammation associated with COVID-19. The largest not-for-profit health system in Texas was selected by sponsor CytoDyn to participate in an ongoing Phase 3 study. In the meantime, the company recently reported impressive results from its Phase 2 clinical trial. Some analysts question why the medical and research establishment is ignoring this promising drug targeting COVID-19 TrialSite appreciated the perspective as dozens in the TrialSite Network have sent inquiries as to why leronlimab doesn’t attract more attention.
Recently, Seeking Alpha’s Thomas Barnard commented on what the TrialSite views as a growing common question: why isn’t this company and drug getting more attention? Mr. Barnard reports on the known facts about the recently announced data from the Phase 1 clinical trial.
· Those patients on leronlimab experienced 63% less Serious Adverse Events than the control group
· Overall 58% less patients impacted by SAE
· The drug actually reduces the viral load in COVID-19 patients to zero in 14 days
· The company will seek an Emergency Use Authorization (EUA) from the FDA to allow patients to address unmet need.
Mr. Barnard via the robust Seeking Alpha online platform offers a solid, well summarized description of the positive attributes of the recent Phase 2 clinical trial sponsored by CytoDyn.
Lack of Even Intellectual Curiosity
TrialSite has received many comments and emails requesting the site look into why leronlimab doesn’t attract more attention. Mr. Barnard’s point of view was recently published hence it made sense to hopefully direct readers to Seeking Alpha to read his point of view.
Although it appears that this drug can possibly reduce suffering associated with more severe COVID-19 cases, the analyst writes “even though the stock went down after the release of these results, and media is ignoring this work, BARDA is ignoring this work, the private foundations are ignoring this work, it nevertheless is important work in reducing suffering.” The “long” holder here suggests considering the unfolding facts in the form of the various clinical trials results, whether for triple negative breast cancer, CTCs, HIV studies and of course now COVID-19.
Company Conference Call
The company’s leadership, Nader Pourhassan, PhD, President and Chief Executive Officer, Scott Kelly, MD, Chairman, Chief Medical Officer and Head of Business Development, and Jacob Lalezari, MD, Senior Science Advisor, will hold an investment community conference call on Thursday, July 30, 2020 to provide a comprehensive update on the Company’s two trials for COVID-19 patients with mild-to-moderate and severe-to-critical indications.
Call to Action: Those interested in learning more about this company from an investment or scientific and medical perspective: it may be worth attending or listening to this event. The webcast can be accessed here.